Galmed Pharmaceuticals Valuation
| GLMD Stock | USD 2.14 0.02 0.93% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Galmed Pharmaceuticals retains a regular Real Value of $2.58 per share. The prevalent price of the firm is $2.14. Our model calculates the value of Galmed Pharmaceuticals from evaluating the firm fundamentals such as Return On Equity of -0.37, return on asset of -0.22, and Shares Owned By Insiders of 1.89 % as well as inspecting its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Galmed Pharmaceuticals' price fluctuation is very risky at this time. Calculation of the real value of Galmed Pharmaceuticals is based on 3 months time horizon. Increasing Galmed Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Galmed stock is determined by what a typical buyer is willing to pay for full or partial control of Galmed Pharmaceuticals. Since Galmed Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Galmed Stock. However, Galmed Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.14 | Real 2.58 | Hype 2.0 | Naive 1.97 |
The real value of Galmed Stock, also known as its intrinsic value, is the underlying worth of Galmed Pharmaceuticals Company, which is reflected in its stock price. It is based on Galmed Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Galmed Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Galmed Pharmaceuticals helps investors to forecast how Galmed stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Galmed Pharmaceuticals more accurately as focusing exclusively on Galmed Pharmaceuticals' fundamentals will not take into account other important factors: Galmed Pharmaceuticals Total Value Analysis
Galmed Pharmaceuticals is currently expected to have valuation of (9.06 M) with market capitalization of 3.55 M, debt of 41 K, and cash on hands of 22.4 M. The negative valuation of Galmed Pharmaceuticals may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Galmed Pharmaceuticals fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(9.06 M) | 3.55 M | 41 K | 22.4 M |
Galmed Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of Galmed is to check how much profit was generated for every dollar of assets it reports. Galmed Pharmaceuticals retains a negative application of resources of -0.22 (percent), losing $0.002198 for each dollar of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of Galmed Pharmaceuticals shows how discouraging it operates for each dollar spent on its resources.Galmed Pharmaceuticals Ownership Allocation
Roughly 95.03 (percent) of Galmed Pharmaceuticals outstanding shares are held by general public with 1.89 % owned by insiders and only 3.08 pct. by outside corporations.Galmed Pharmaceuticals Profitability Analysis
Net Loss for the year was (6.91 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Galmed Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Galmed Pharmaceuticals and how it compares across the competition.
About Galmed Pharmaceuticals Valuation
The stock valuation mechanism determines Galmed Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Galmed Pharmaceuticals. We calculate exposure to Galmed Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Galmed Pharmaceuticals's related companies.Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel. Galmed Pharmaceutica operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 19 people.
Galmed Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Galmed Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 230.8 K |
Complementary Tools for Galmed Stock analysis
When running Galmed Pharmaceuticals' price analysis, check to measure Galmed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galmed Pharmaceuticals is operating at the current time. Most of Galmed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Galmed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galmed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Galmed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |